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Fraud in biomedical research — The role of journal Editors☆1. Introduction
A fewmonths ago (February 28 2011) wewere informed, through a
reader-scholar in the discipline, that an original manuscript, published
by Vascular Pharmacology (Sheikpranbabu et al., 2010), was highly sus-
picious for fraud. The allegations were that ﬁgures in the manuscript,
meant to be original ﬁgures of a cell culture dish in angiogenesis assays,
were digitally manipulated, providing evidence of fabrication.
In inspecting a few othermanuscripts from the same group,we later
found strong suspicions of similar digital manipulations for published
images at least in two other papers, published by two other journals,
namely Angiogenesis (Kalishwaralal et al., 2011) and Life Sciences
(Sheikpranbabu et al., 2009).
After internal consultations among the Editors of the journals where
such research had been published, we agreed that the evidence for
fraud was beyond any reasonable doubt, and decided to take a concerted
action on this. This Editorial frames our recent ﬁndings in the broader
context of the literature and describes the consequent action taken by
the Editors, with the aim of providing a reference for possible future sim-
ilar cases.
2. The broader picture — the prevalence of the problem
Fraud in biomedical sciences probably has always existed. Widely
publicized cases in the past, such as the Darsee (Relman, 1983) and
Slutky affairs (Engler et al., 1987), have however considerably raised
the interest in the topic and dismantled the belief that all biomedical
research is done in good faith, that fraud is exceptionally rare, and
usually detected by an accurate peer review process and by lack of
replication of the original ﬁndings.
In a recent report (Fanelli, 2009), a pooledweighted average of 1.97%
(95% CI: 0.86-4.45) of scientists admitted to have fabricated, falsiﬁed or
modiﬁed data or results at least once – a serious form of misconduct by
any standard – and up to 33.7% admitted other questionable research
practice. Considering that these surveys ask sensitive questions and
have other limitations, it appears likely that these are conservative esti-
mates of the true prevalence of scientiﬁc misconduct.
3. Detection of fraud
As pointed out in a review paper on the same topic (Engler et al.,
1987), research fraud may evade detection, and “there are scientists
prepared to run the appreciable risk of submitting inaccurate state-
ments for publication”. The sophistication of fraud, especially at☆ Note to readers: This article has also been published in Life Sciences, doi:10.1016/j.
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Open access under CC BY-NC-ND license.times when digital processing of images has become routine, may also
escape detection by reviewers and editors. The view that conﬁrmation
of results by others is the ultimate judgment on the validity of published
results appears to downplay – in our opinion – the damage in credit,
ethics and trust that biomedical research receives for such behavior —
a true “poisoning of the well” (Smith, 2006). The probability that lack
of replication can be a solution to the poisoning is remotely small,
given the low priority usually given to publishing papers investigating
and attempting at replicating previously published ﬁndings, and given
the time lag that replication usually requires. The current emphasis on
competition and the pressure to publish may favor personal career
goals over the motivation of scientists to pursue the truth. As a conse-
quence, and even recognizing that fraud largely originates from an indi-
vidual propensity to it, there should bemeasures set forth by individual
institutions and granting agencies to investigate suspected fraud and to
increase the awareness of the problem, still avoiding – as much as pos-
sible – a “witch hunt” atmosphere that could stiﬂe originality and dis-
courage collaborative research (Engler et al., 1987).4. What to do with the problem
Solutions to the problem are not simple and involve a diffuse re-
sponsibility of many: from teaching and tutoring on the responsibilities
of authorship (Vollmer, 2007), to providing internal guidelines or rules
at institutions to control data gathering and recording of results, to
explaining and advertising the role of supervisors and senior authors,
to advertising description of the expected ethical behavior by all parties
involved in the publishing process (see, for example: http://www.
elsevier.com/wps/ﬁnd/intro.cws_home/publishing). Some of the re-
sponsibility in the process must also lie however with biomedical jour-
nals. This was the case we were confronted with and for which we, as
Editors, should increasingly be prepared to act in the future.
Journals are not those who should investigate accusations. It has
been rightly argued that the fact that an author has published a
study in a journal does not give the journal the legal legitimacy to in-
vestigate even that particular study (Smith, 2005). Bodies that clearly
have legal legitimacy to conduct investigations on previous publica-
tion of an accused employee are the accused's employer; usually a
university, a medical school, or a hospital, in the case of a medical re-
searcher (Smith, 2005). However the Editors of medical and scientiﬁc
journals, who have done much to draw attention to the problem in
the past, should – in our opinion – do more to help in coping with
it. Rather than simply rejecting articles they ﬁnd suspicious, they
should be encouraged to express concerns to the author or contact
the named designated person in the organization that employs the
lead author, or both (Farthing, 1998). We ﬁnd the reluctance of
some Editors to retract the paper themselves, even in overtly clear
120 Prefacecases of fraud, instead simply asking the authors to do so, to be a way
of delegating some of their important responsibility in preventing or
ﬁghting the problem.
Although usually the investigators' employers should hold an inves-
tigation and hearing and reach a conclusion whether fraud exists, jour-
nals clearly have an inescapable duty to inform readers if the published
papers prove to be fraudulent. Journals are in any case privileged whis-
tleblowers in the process (Smith, 2005). One reason for this privilege is
that their reviewers or readers are usually the ﬁrst to suspect scientiﬁc
misconduct — thus the journals serve the role of ﬁrst sentinels against
fraud. Another reason is they are hard to attack. Reviewers or readers
spotting or suspecting fraud usually refer to the journals, rather than
to employers in the case of suspicions of fraud: in most cases because
they are much more vulnerable. Their will to remain anonymous in
the process is perfectly understandable. The job of the journal, once
alerted of a problem, is therefore usually to ask another body – normally
the employer – to investigate. They also have however a duty to make
sure that the responsible body called into action really does act. If this
does not happen, then the journal may have to do so. This should take
place even though lawyers, based on the fact that journals cannot easily
undertake a thorough investigation, usually advise them against (Smith,
2005).
5. What we did
In the case that occurred to us, the evidence for fraudwas clear once
we were alerted where to look. Despite having escaped peer review
processes by six reviewers and a scrutiny by three Editors, we felt
fraud was clear beyond any reasonable doubt. Our consequent action
was stepwise.
• The Editors of Vascular Pharmacology ﬁrst notiﬁed (March 29 2011)
the senior author that a concern had been raised by an independent
source that the images in the above-referred paper had been inappro-
priatelymanipulated before publication, asking him to go through the
entire paper, with particular attention to the ﬁgures, and report to us
within a deadline of about 15 days.
• Upon receiving an unsatisfactory reply (April 2 2011) on the nature of
the problem,we disclosed (April 12 2011) the allegations fully, point-
ing out exactly where the evidence for fabrication was detected.
• Upon receiving (April 24 2011) a further letter of excuses still claiming
the absence of fraud, we notiﬁed (May 24 2011) the matter to the
Chancellor of the University, asking the University to establish an in-
ternal committee to investigate the matter in full. At the same time,
similar letters were sent by the Editors of Life Sciences (June 14
2011) and Angiogenesis (July 17 2011). At the same time we took a
proactive action in retracting ourselves the papers involved, without
waiting for the Authors' retraction.
• On August 6 we received a notiﬁcation by the University that the
following action had taken place:
1. Dr. G. Sangliyandi, Senior Professor andHead, Department of Biotech-
nology, and Dean, International Relations, Kalasalingam University,
was directed to resign from the KalasalingamUniversity immediately
and hand over the charges to Dr. K. Sundar, Professor, Department of
Biotechnology. (Dr. G. Sangliyandi has resigned on 5th August 2011)
2. The Ph.D. Registration of the following Research Scholars was can-
celed (They are the ﬁrst author of papers in which scientiﬁc misconduct
was found).
a. Ms. E. Banumathi (Full Time) Reg. No: 200701101
b. Mr. S. Sheik Pran Babu (Full Time) Reg. No: 200701102
c. Mr. R. Haribalaganesh (Full Time) Reg. No: 200801106
d. Mr. K. Kalishwarlal (Full Time) Reg. No: 2009011203. The conﬁrmation of the Ph.D. registration of the following Research
Scholars was canceled. (They are the co-authors of papers in which
scientiﬁc misconduct was found.)
a. Mr. V. Deepak (Full Time) Reg. No: 200901119
b. Mr. S. Ramkumar Pandian (Full Time) Reg. No: 200901121
We, as Editors of the journals in question where the fraudulent
original research was published, believe that the action instituted
on this matter was correct, timely and appropriate. We also hope
that disclosure of such policy may help providing guidance in similar
cases and ﬁghting the problem.
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